NasdaqHealth CareHealth Care ServicesS&P MidCap 400
$67.15
+1.29 (+1.96%)
Close of Nov 06, 2026 · end-of-day data
BTSG 8-K filings in 2025
Every material Form 8-K BrightSpring Health Services filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
BrightSpring Health Services reported third-quarter 2025 revenue of $3,334 million, up 28.2% from a year earlier, and Adjusted EBITDA of $160 million, up 37.2%. The company raised its full-year 2025 revenue guidance and reiterated its Adjusted EBITDA guidance, which matters to shareholders because the headline sales and profit measures both improved.
Q3 2025 revenue was $3,334 million, up 28.2% from $2,601 million; continuing-operations net income was $37.5 million versus a net loss of $25.7 million a year earlier.
Adjusted EBITDA was $160 million, up 37.2% from $117 million.
2025 revenue guidance was raised to $12,500 million to $12,800 million; Adjusted EBITDA guidance of $605 million to $615 million was reiterated.
The planned sale of the Community Living business to Sevita is expected to close in Q1 2026.
BrightSpring Health Services agreed on October 20, 2025 to an underwritten secondary offering of 15,000,000 common shares sold by KKR Phoenix Aggregator L.P. and management stockholders, closing October 22, 2025. The company received no proceeds, but it separately repurchased 1,500,000 shares from the underwriter, BofA Securities, with no underwriting fee.
Selling stockholders sold all 15,000,000 shares of common stock in the offering, led by KKR Phoenix Aggregator L.P. and management sellers.
BrightSpring bought back 1,500,000 shares from BofA Securities as part of the offering; the underwriter received no fee on those shares.
The company received no offering proceeds, apart from cash from management stock option exercises.
The offering was made under an automatic shelf registration filed June 10, 2025; the underwriting agreement is filed as Exhibit 1.1.
BrightSpring Health Services reported preliminary third-quarter 2025 results for continuing operations, with revenue of approximately $3,334 million, up 28.2%, and Adjusted EBITDA of approximately $160 million, up 37.2%. The company raised its full-year 2025 revenue and Adjusted EBITDA guidance, which excludes the pending Community Living divestiture to Sevita. The results are preliminary, and full third-quarter results will be announced on October 28, 2025.
Q3 2025 revenue of approximately $3,334 million, up 28.2% from approximately $2,601 million; Adjusted EBITDA of approximately $160 million, up 37.2% from approximately $117 million.
Q3 2025 net income of approximately $37.5 million, compared with a net loss of approximately $25.7 million in Q3 2024.
2025 revenue guidance raised to $12,400 million to $12,700 million; Adjusted EBITDA guidance raised to $605 million to $615 million.
Community Living divestiture to Sevita is expected to close in early Q1 2026; full Q3 results and conference call on October 28, 2025.
BrightSpring Health Services reported second-quarter 2025 results on August 1, 2025, with net revenue up 29.1% and Adjusted EBITDA up 28.8%, both excluding the Community Living business. The company raised its full-year 2025 revenue and Adjusted EBITDA guidance, while net income from continuing operations was flat at $8.5 million. The planned sale of Community Living to Sevita is expected to close in the fourth quarter of 2025.
Q2 2025 net revenue was $3,148 million, up 29.1% from $2,438 million a year earlier.
Adjusted EBITDA was $143 million, up 28.8% from $111 million; net income from continuing operations was $8.5 million, flat year over year.
2025 revenue guidance was raised to $12,200 million-$12,600 million, and Adjusted EBITDA guidance to $590 million-$605 million.
The Community Living divestiture to Sevita, announced January 20, 2025, is expected to close in Q4 2025.
BrightSpring said Michael McMaude resigned on June 20, 2025 as President of Hospice Services and as CEO of subsidiary Abode Healthcare, effective immediately, and that he is not leaving over any disagreement with the company. He will continue as a non-employee consultant through the earlier of January 26, 2027 or early termination, under a Resignation Agreement that the filing says includes stock option and equity provisions, and restrictive covenants.
Resigned as President of Hospice Services and CEO of Abode Healthcare, effective June 20, 2025
Consulting period runs until the earlier of January 26, 2027 or early termination
Consulting fee of $2,000 per month, plus $12,000 for the first 45 days, plus pre-approved expenses
Unvested options, RSUs and phantom shares keep vesting during consulting; full filing attached as Exhibit 10.1
BrightSpring filed an 8-K describing an underwritten offering of 14,000,000 common shares at $21.75 per share, sold entirely by selling stockholders led by KKR Phoenix Aggregator L.P. The company did not receive proceeds from the sale, apart from cash from management option exercises, and the offering closed on June 12, 2025. The filing shows a secondary sale of existing shares rather than new capital raised by the company.
Offering: 14,000,000 shares of common stock at a public price of $21.75 per share, before underwriting discounts and commissions
Selling stockholders include KKR Phoenix Aggregator L.P. and management; the underwriters have a 30-day option to buy up to 2,100,000 more shares from KKR
Company received no offering proceeds, other than cash from management stock option exercises
Underwriting agreement dated June 10, 2025; closing occurred June 12, 2025
BrightSpring reported first quarter 2025 results on May 2, 2025, with net revenue of $2,878 million, up 25.9%, and net income from continuing operations of $9.2 million, compared with a loss of $56.0 million a year earlier. The company raised its full-year 2025 revenue guidance to $12,000 million to $12,500 million and Adjusted EBITDA guidance to $570 million to $585 million, and said the planned sale of its Community Living business to Sevita remains on track this year.
Net revenue of $2,878 million, up 25.9% from $2,286 million in Q1 2024
Net income from continuing operations of $9.2 million, versus a net loss from continuing operations of $56.0 million in Q1 2024
Adjusted EBITDA of $131 million, up 28.2% from $102 million
2025 guidance raised: revenue of $12,000 million to $12,500 million; Adjusted EBITDA of $570 million to $585 million
BrightSpring reported fourth-quarter and full-year 2024 results and raised its 2025 revenue and Adjusted EBITDA guidance, excluding the Community Living business it agreed on January 20, 2025 to sell to Sevita for $835 million. Full-year net loss narrowed to $20.5 million from $156.8 million in 2023, while revenue and Adjusted EBITDA both grew.
Q4 2024 net revenue of $3,053 million, up 28.6%; Q4 net income of $15.4 million versus a net loss of $7.2 million in Q4 2023
Full-year 2024 net revenue of $11,266 million, up 27.6%; Adjusted EBITDA of $588 million, up 9.3%
2025 guidance raised: revenue of $11,600 million to $12,100 million and Adjusted EBITDA of $545 million to $560 million, excluding Community Living
Community Living divestiture to Sevita for $835 million, subject to customary closing adjustments
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every BrightSpring Health Services filing is on SEC EDGAR ↗. 8-K briefs of other companies →